Alyssa N. Coyne

Alyssa N. Coyne

Auto-generated profile, based on publicly available information

Alyssa N. Coyne

Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2022 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
EBEmily G. Baxi
Emily G. Baxi
TTTerri Thompson
Terri Thompson
JLJonathan Li
Jonathan Li
JKJulia A. Kaye
Julia A. Kaye
RLRyan G. Lim
Ryan G. Lim
JRJeffrey D. Rothstein
Jeffrey D. Rothstein
Answer ALS is a biological and clinical resource of patient-derived, induced pluripotent stem (iPS) cell lines, multi-omic data derived from iPS neurons and longitudinal clinical and smartphone data from over 1,000 patients with ALS. This resource provides population-level biological and clinical data that may be employed to identify clinical–molecular–biochemical subtypes of amyotrophic lateral sclerosis (ALS). A unique smartphone-based system was employed to collect deep clinical data, including fine motor activity, speech, breathing and linguistics/cognition. The iPS spinal neurons were blood derived from each patient and these cells underwent multi-omic analytics including whole-genome sequencing, RNA transcriptomics, ATAC-sequencing and proteomics. The intent of these data is for the generation of integrated clinical and biological signatures using bioinformatics, statistics and computational biology to establish patterns that may lead to a better understanding of the underlying mechanisms of disease, including subgroup identification. A web portal for open-source sharing of all data was developed for widespread community-based data analytics.

28 July 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ACAlyssa N. Coyne
Alyssa N. Coyne
VBVictoria Baskerville
Victoria Baskerville
BZBenjamin L. Zaepfel
Benjamin L. Zaepfel
DDDennis W. Dickson
Dennis W. Dickson
FRFrank Rigo
Frank Rigo
JRJeffrey D. Rothstein
Jeffrey D. Rothstein
Alterations in the components [nucleoporins (Nups)] and function of the nuclear pore complex (NPC) have been implicated as contributors to the pathogenesis of genetic forms of neurodegeneration including C9orf72 amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD). We hypothesized that Nup alterations and the consequential loss of NPC function may lie upstream of TDP-43 dysfunction and mislocalization widely observed in ALS, FTD, and related neurodegenerative diseases. Here, we provide evidence that CHMP7, a critical mediator of NPC quality control, is increased in nuclei of C9orf72 and sporadic ALS induced pluripotent stem cell (iPSC)–derived spinal neurons (iPSNs) and postmortem human motor cortex before the emergence of Nup alterations. Inhibiting the nuclear export of CHMP7 triggered Nup reduction and TDP-43 dysfunction and pathology in human neurons. Knockdown of CHMP7 alleviated disease-associated Nup alterations, deficits in Ran GTPase localization, defects in TDP-43–associated mRNA expression, and downstream glutamate-induced neuronal death. Thus, our data support a role for altered CHMP7-mediated Nup homeostasis as a prominent initiating pathological mechanism for familial and sporadic ALS and highlight the potential for CHMP7 as therapeutic target.

29 April 2022 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
ACAlyssa N. Coyne
Alyssa N. Coyne
JRJeffrey D. Rothstein
Jeffrey D. Rothstein

27 October 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
JBJessica A. Bush
Jessica A. Bush
HAHaruo Aikawa
Haruo Aikawa
RFRita Fuerst
Rita Fuerst
YLYue Li
Yue Li
AUAndrei Ursu
Andrei Ursu
MDMatthew D. Disney
Matthew D. Disney
Small-molecule recruitment of an endogenous nuclease rescues pathologies associated with c9ALS/FTD in vivo by targeting an RNA repeat expansion.

25 June 2025 in Nature
Verified
Journal Article
Closed access
PDF file
JHJames H. Hurley
James H. Hurley
ACAlyssa N. Coyne
Alyssa N. Coyne
MMMarta Miączyńska
Marta Miączyńska
HSHarald Stenmark
Harald Stenmark

29 February 2024 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
CMCarmelo Milioto
Carmelo Milioto
MCMireia Carcolé
Mireia Carcolé
AGAshling Giblin
Ashling Giblin
RCRachel Coneys
Rachel Coneys
OAOlivia Attrebi
Olivia Attrebi
AIAdrian M. Isaacs
Adrian M. Isaacs
Dipeptide repeat proteins are a major pathogenic feature of C9orf72 amyotrophic lateral sclerosis (C9ALS)/frontotemporal dementia (FTD) pathology, but their physiological impact has yet to be fully determined. Here we generated C9orf72 dipeptide repeat knock-in mouse models characterized by expression of 400 codon-optimized polyGR or polyPR repeats, and heterozygous C9orf72 reduction. (GR)400 and (PR)400 knock-in mice recapitulate key features of C9ALS/FTD, including cortical neuronal hyperexcitability, age-dependent spinal motor neuron loss and progressive motor dysfunction. Quantitative proteomics revealed an increase in extracellular matrix (ECM) proteins in (GR)400 and (PR)400 spinal cord, with the collagen COL6A1 the most increased protein. TGF-β1 was one of the top predicted regulators of this ECM signature and polyGR expression in human induced pluripotent stem cell neurons was sufficient to induce TGF-β1 followed by COL6A1. Knockdown of TGF-β1 or COL6A1 orthologues in polyGR model Drosophila exacerbated neurodegeneration, while expression of TGF-β1 or COL6A1 in induced pluripotent stem cell-derived motor neurons of patients with C9ALS/FTD protected against glutamate-induced cell death. Altogether, our findings reveal a neuroprotective and conserved ECM signature in C9ALS/FTD.